MARTINDALE PHARMA
Making lives better

Building A2
Glory Park
Wooburn Green
High Wycombe
HP10 0DF
United Kingdom

t +44 (0) 1628 551900
f +44 (0) 1628 529848
e connect@martindalepharma.co.uk
w martindalepharma.co.uk

Date

Direct Communication to patients, carers and community workers who have been supplied with Prenoxad Injection
Information regarding correcting an historic error in the Prenoxad formulation.

You have been provided with Prenoxad Injection as Take Home Naloxone. We have made a change to the formulation of Prenoxad Injection and increased the amount of active ingredient (naloxone hydrochloride) in the product, from 0.91 mg/ml to 1 mg/ml**.**

There are no implications as regards the clinical effect or **how the product is used**.

'New formulation' will appear on the packaging to differentiate between product that has already been released to market and the reformulated product.

Please use the product as directed by your service provider, case worker or doctor.

The old formulation of Prenoxad may still be used in the meantime.

Call for reporting:
Patients or carers can report any suspected adverse reactions to the Medicine and Healthcare products Regulatory Agency via the Yellow Card Scheme. It is easiest and quickest to report online via the Yellow Cards website https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Pharmacovigilance department in Aurum Pharmaceuticals Ltd (an entity of Martindale Pharma):
Email: drugsafety@martindalepharma.co.uk

If you require any further clarification or have any questions, please contact Martindale Pharma Medical Information at medinfo@martindalepharma.co.uk.